Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ФГАОУ ВО «Российский университет дружбы народов им. Патриса Лумумбы», Москва, Россия omekan@mail.ru
Список исп. литературыСкрыть список 1. World health organization. 2022. 2. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/ obesity-and-overweight 3. Успенский Ю.П., Петренко Ю.В., Гулунов З.Х. и др. Метаболический синдром. Учебное пособие. СПб., 2017. Uspensky Yu.P., Petrenko Yu.V., Gulunov Z.Kh. et al. Metabolic syndrome. Tutorial. SPb., 2017 (in Russian). 4. Avgerinos KI, Spyrou N, Mantzoros CS, Dalamaga M. Obesity and cancer risk: Emerging biological mechanisms and perspectives. Metabolism 2019; 92: 121–35. 5. Оразов М.Р., Радзинский В.Е., Хамошина М.Б. и др. Metabesity у женщин: долгосрочные последствия для здоровья. Доктор.Ру. 2023; 22 (1): 11–5. DOI: 10.31550/1727-2378-2023-22-1-11-15 Orazov M.R., Radzinsky V.E., Khamoshina M.B. et al. Metabesity in women: long-term health consequences. Doctor.Ru. 2023; 22 (1): 11–5. DOI: 10.31550/1727-2378-2023-22-1-11-15 (in Russian). 6. Global Cancer Observatory. Available at: https://gco.iarc.fr 7. WHO Classification of Tumours Editorial Board. Female Genital Tumours. Vol 4. 5th ed. Lyon, 2020. 8. Reed SD, Newton KM, Clinton WL et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009; 200 (6): 678-e1. 9. Petersdorf K, Groettrup-Wolfers E, Overton PM et al. Endometrial hyperplasia in pre-menopausal women: A systematic review of incidence, prevalence, and risk factors. Eur J Obstet Gynecol Reprod Biol 2022; 271: 158–71. 10. Chae-Kim J, Garg G, Gavrilova-Jordan L et al. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis. Int J Gynecol Cancer 2021; 31: 1499–505. DOI: 10.1136/ijgc-2021-002699 11. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985; 56 (2): 403–12. DOI: 10.1002/1097-0142(19850715)56: 23.0.co;2-x 12. Пономаренко И.В., Верзилина И.Н., Сорокина И.Н. и др. Полиморфизм rs222003 гена GC как предиктор развития гиперплазии эндометрия. Вопросы гинекологии, акушерства и перинатологии. 2019; 18 (6): 28–33. Ponomarenko I.V., Verzilina I.N., Sorokina I.N. et al. Polymorphism rs222003 of the GC gene as a predictor of the development of endometrial hyperplasia. Issues of gynecology, obstetrics and perinatology. 2019; 18 (6): 28–33 (in Russian). 13. Lacey JV Jr, Chia VM. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009; 63 (1): 39–44. DOI: 10.1016/j.maturitas.2009.02.005 14. Оразов М.Р., Михалева Л.М., Орехов Р.Е. и др. Профилактика гиперплазий эндометрия в репродуктивном периоде. Вопросы гинекологии, акушерства и перинатологии. 2022; 21 (1): 101–6. DOI: 10.20953/1726-1678-2022-1-101-106 Orazov M.R., Mikhaleva L.M., Orekhov R.E. et al. Prevention of endometrial hyperplasia in the reproductive period. Issues of gynecology, obstetrics and perinatology. 2022; 21 (1): 101–6. DOI: 10.20953/1726-1678-2022-1-101-106 (in Russian). 15. Оразов М.Р. Дискуссионные вопросы ведения пациенток с гиперплазией эндометрия. Акушерство и гинекология. 2016; 3: 46–58. Orazov M.R. Controversial issues in the management of patients with endometrial hyperplasia. Obstetrics and gynecology. 2016; 3: 46–58 (in Russian). 16. Orbo A, Arnes M, Vereide AB, Straume B. Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens. BJOG 2016; 123 (9): 1512–9. DOI: 10.1111/1471-0528.13763 17. Chandra V, Kim JJ, Benbrook DM et al. Therapeutic options for management of endometrial hyperplasia. J Gynecol Oncol 2016; 27 (1). 18. Morice P, Leary A, Creutzberg C et al. Endometrial cancer. Lancet 2016; 387 (10023): 1094–108. 19. Gibson DA, Saunders PT. Estrogen dependent signaling in reproductive tissues – a role for estrogen receptors and estrogen related receptors. Mol Cell Endocrinol 2012; 348 (2): 361–72. 20. Gibson DA, Saunders PT. Endocrine disruption of oestrogen action and female reproductive tract cancers. Endocr Relat Cancer 2014; 21 (2): T13–31. 21. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985; 56: 403–12. 22. Montgomery BE, Daum GS, Dunton CJ. Endometrial hyperplasia: a review. Obstet Gynecol Surv 2004; 59: 368–78. 23. Tahergorabi Z, Khazaei M, Moodi M, Chamani E. From obesity to cancer: a review on proposed mechanisms. Cell Biochem Function 2016; 34 (8): 533–45. 24. Оразов М.Р., Михалева Л.М., Муллина И.А., Леффад Л.М. Патогенез рецидивирующей гиперплазии эндометрия без атипии. Трудный пациент. 2021; 19 (6): 36–9. DOI: 10.224412/2074-1005-2021-6-36-39 Orazov M.R., Mikhaleva L.M., Mullina I.A., Leffad L.M. Pathogenesis of recurrent endometrial hyperplasia without atypia. Difficult patient. 2021; 19 (6): 36–9. DOI: 10.224412/2074-1005-2021-6-36-39 (in Russian). 25. Slettenn ET, Arnes M, Lysa LM et al. Prediction of relapse after therapy withdrawal in women with endometrial hyperplasia: a long-term follow-up study. Anticancer Res 2017; 37: 2529–36. 26. Fazleabas AT, Braundmeier A, Parkin K. Endometriosis-Induced Changes in Regulatory T Cells – Insights Towards Developing Permanent Contraception. Contraception. Published online. 2015. DOI: 10.1016/j.contraception.2015.06.006 27. Khan D, Patel R. Role of immune dysregulation in the pathogenesis of endometrial hyperplasia. 2022. 28. Polikarpova AV, Levina IS, Sigai NV et al. Immunomodulatory e ff ects of progesterone and selective ligands of membrane progesterone receptors. Steroids 2019; 145 (January): 5–18. DOI: 10.1016/j.steroids. 2019.02.009 29. Reed SD, Newton KM, Clinton WL et al. Incidence of endometrial hyperplasia. Am J Obstet Gynecol 2009; 200 (6): 678.e1-6. DOI: 10.1016/j.ajog.2009.02.032 30. Федеральные клинические рекомендации «Гиперплазия эндометрия». 2021. Federal clinical guidelines “Endometrial hyperplasia”. 2021 (in Russian). 31. American’s College of Obstetricians and Gynecologists (ACOG). Guideline «Management of Endometrial Intraepithelial Neoplasia or Atypical Endometrial Hyperplasia», September 1, 2023. 32. Erratum to “Guideline No. 390-Classification and Management of Endometrial Hyperplasia” [Journal of Obstetrics and Gynaecology Canada 41/12 (2019) 1789–1800]. J Obstet Gynaecol Canada 2020; 42 (10). 33. Singh G, Puckett Y. Endometrial Hyperplasia. [Updated 2023 Jul 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK560693/ 34. Vereide AB, Arnes M, Straume B et al. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2003; 91: 526–33. 35. Güven M, Dikmen Y, Terek MC et al. Metabolic effects associated with high-dose continuous megestrol acetate administration in the treatment of endometrial pathology. Arch Gynecol Obstet 2001; 265: 183–6. 36. Gal D, Edman CD, Vellios F, Forney JP. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol 1983; 146: 316–22. 37. Brun JL, Belaisch J, Rivel J, Hocké C. Endometrial hyperplasias resistant to progestins: alternatives to traditional treatments. Gynecol Obstet Fertil 2002; 30: 244–51. 38. Philibert D, Bouchoux F, Degryse M et al. The pharmacological profile of a novel norpregnance progestin (trimegestone). Gynecol Endocrinol 1999; 13 (5): 316–26. DOI: 10.3109/09513599909167574 39. Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev 2013; 34 (2): 171–208. DOI: 10.1210/er.2012-1008 40. Давыдов А.И., Шахламова М.Н., Новрузова Н.Х. Субмукозная миома матки и гиперплазия эндометрия: принципы лечения в репродуктивном периоде. Вопросы гинекологии, акушерства и перинатологии. 2020; 19 (2): 136–42. Davydov A.I., Shakhlamova M.N., Novruzova N.Kh. Submucous uterine fibroids and endometrial hyperplasia: principles of treatment in the reproductive period. Issues of gynecology, obstetrics and perinatology. 2020; 19 (2): 136–42 (in Russian). 41. Fraser IS, Kovacs GT. The efficacy of non-contraceptive uses for hormonal contraceptives. Med J Aust 2003; 178 (12): 621–3. DOI: 10.5694/j.1326-5377.2003.tb05387.x 42. Maia HJr, Casoy J, Correia T et al. Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis. Gynecol Endocrinol 2006; 22 (10): 547–51. DOI: 10.1080/09513590601005375 43. Iversen L, Fielding S, Lidegaard Ø, Hannaford PC. Contemporary hormonal contraception and risk of endometrial cancer in women younger than age 50: a retrospective cohort study of Danish women. Contraception 2020; 102 (3): 152–8. 44. He Y, Wang J, Wang Y et al. Maintenance Therapy Can Improve the Oncologic Prognosis and Obstetrical Outcome of Patients With Atypical Endometrial Hyperplasia and Endometrial Cancer After Fertility-Preserving Treatment: A Multicenter Retrospective Study. Front Oncol 2021; 11: 808881. 45. Wang Y, Nisenblat V, Tao L et al. Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience. J Gynecol Oncol 2019; 30 (3).